Xconomy | San Diego - Business + Technology in the Exponential Economy

Regulus Hits GSK Milestone

Luke Timmerman 5/14/09

Regulus Therapeutics, the Carlsbad, CA-based developer of drugs that block microRNA targets, said today it has reached the first milestone as part of its partnership with GlaxoSmithKline. Regulus has delivered specific microRNA blockers, known as anti-MIRs, in mice, and shown how they change the expression of genes in immune cells. Regulus didn’t disclose any financial terms related to reaching the milestone. Regulus was founded as a joint venture of Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) and Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY).

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments (1) | Reprints | Share:

Links to This Post

Regulus Hits GSK Milestone | Xconomy « Biotech Beach Bum
5/19/09 10:53 am

[...] Regulus Hits GSK Milestone | Xconomy Regulus’s new microRNA blocker technology (aka anti-MIR) hits its first milestone for marketing/funding partner GSK. This promising approach delivers small pieces of RNA into cells to block transcription and thereby slow gene expression. http://www.xconomy.com/san-diego/2009/05/14/regulus-hits-gsk-milestone/ [...]